Engineered stem cell therapy takes on Hard-to-Treat myeloma
NCT ID NCT05182073
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tested a new therapy called FT576, made from specially engineered stem cells that become cancer-fighting immune cells. It was given alone or with another drug, daratumumab, to 31 people with multiple myeloma that had returned or stopped responding to prior treatments. The goal was to find a safe dose and see if the therapy could shrink the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FT576 (engineered immune cells from stem cells) and daratumumab (a targeted antibody)
What this could lead to
If successful, this could point toward a new treatment option for multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is an early Phase 1 trial with only 31 participants, so safety and effectiveness are not yet proven. The treatment may cause side effects or fail to control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Medical Oncology Hematology Consultants
Newark, Delaware, 19713, United States
-
Oncology Hematology Care, Inc
Cincinnati, Ohio, 45226, United States
-
Roswell Park
Buffalo, New York, 14263, United States
-
Scri-Cbci
Denver, Colorado, 80218, United States
-
Tennessee Oncology - Nashville
Nashville, Tennessee, 37203, United States
-
Texas Oncology-Medical City Dallas
Dallas, Texas, 75230, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35205, United States
-
University of Minnesota
Saint Paul, Minnesota, 55108, United States
-
Virginia Oncology Associates
Norfolk, Virginia, 23502, United States
-
Washington University
St Louis, Missouri, 63130, United States